DOCSLIB.ORG

Genes in Tumorigenesis of Human Colorectal Cancers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genes in Tumorigenesis of Human Colorectal Cancers 81-91 11/12/07 12:26 Page 81 ONCOLOGY REPORTS 19: 81-91, 2008 81 Significance of the glycolytic pathway and glycolysis related- genes in tumorigenesis of human colorectal cancers CHING-SHENG YEH1,7, JAW-YUAN WANG2,5, FU-YEN CHUNG1, SU-CHEN LEE4, MING-YII HUANG1,6, CHIA-WEI KUO3, MING-JE YANG1 and SHIU-RU LIN3 1Graduate Institute of Medicine, 2Faculty of Medicine, 3Graduate Institute of Medical Genetics and 4Department of Clinical Laboratory, College of Medicine, Kaohsiung Medical University; Departments of 5Surgery, 6Radiation Oncology and 7Labortory, Kaohsiung Medical University Hospital, Kaohsiung 80317, Taiwan, R.O.C. Received June 13, 2007; Accepted August 17, 2007 Abstract. We investigated gene expressions involved in the new cases and 200,000 deaths due to CRC are reported in glycolytic pathways in colorectal cancer. The study was these areas (1-3). CRC is also one of the most frequent designed to use gene ontology and its relevant bioinformatics malignancies and has the third highest mortality rate of all tools to analyze the microarray data obtained from CRC tissues the cancers in Taiwan, affecting and causing over 7,000 new and their corresponding normal tissues, in order to explore cases and 3,000 deaths per year (4-6). As investigative studies the correlation between the glycolytic metabolic pathway and have reported, approximately 30-40% of CRC patients who possible pathogenesis of this disease. The overexpression of have undergone curative resection afterwards develop glycolysis-related genes was observed in over 76% of CRC metastatic disease and die within 5 years (7,8). tissues. In addition, we stimulated the SW480 and SW620 Little is known about the details of the molecular CRC cell lines with 15 mM D-(+)-glucose and 10 mM 2- mechanism of CRC development; therefore, difficulties exist deoxy-D-glucose respectively. The results indicate that the in its prevention and treatment. Consequently, knowing how to proliferation response of both the SW480 and SW620 cell rapidly organize new techniques for exploring the molecular lines increased remarkably with a time-dependent effect by mechanisms of CRC is key to providing researchers with D-(+)-glucose administration. In contrast, the proliferation the information regarding detailed functional analyses of response of both the SW480 and SW620 cell lines was turmorigenesis. In order to explore the molecular mechanisms significantly inhibited by 2-DG administration. Likewise, underlying the tumorigenesis of CRC, high-throughput and further analyses of the expression of related genes triggered efficient tools are used, such as comparative genomic by the D-(+)-glucose in vivo show that the activation process hybridization (CGH), microarray and proteomics, which can of these eight genes - GLUT1, HK1, GPI, GAPD, PGK1, analyze the activation of differential molecular factors PGK2, ENO2, PKM2 - prominently increased with a time- between the normal mucosal tissues and the cancerous dependent effect. In conclusion, this study demonstrates that tissues. Afterwards bioinformatics tools are employed to the glycolytic pathway and glycolysis-related genes may play predict the relevant mechanisms of CRC turmorigenesis. an important role in the tumorigenesis of CRC, but their Previously, we have observed that constructed membrane- molecular mechanisms need further investigation to verify this. array techniques can be effective and efficient for the confirmation of overexpression of related genes in human Introduction cancerous tissues (9-11). Recently, we have demonstrated that fatty acid metabolism plays an important role in turmori- Colorectal cancer (CRC) is a primary cause of morbidity and genesis of human CRCs by microarray-bioinformatics analysis mortality in Europe and the USA. Each year, about 300,000 (12). We have also obtained preliminary results from the same experiments that indicate the glycolysis pathway might be imperative for tumorigenesis of CRC. Although several _________________________________________ studies have proved that malignant tumor cells increase the glycolytic activity in many malignant diseases in vivo and Correspondence to: Dr Shiu-Ru Lin, Graduate Institute of in vitro (13-16), whether the glycolytic pathway and Medical Genetics, College of Medicine, Kaohsiung Medical glycolysis-related genes participate in tumorigenesis of University, Kaohsiung 80317, No. 100, Shin-Chuan 1st Road, human CRC has yet to be elucidated. Taiwan, R.O.C. In this study therefore, we first attempted to verify the E-mail: [email protected] activation of these genes relevant to the glycolytic pathway in human CRC tissues. Moreover, we stimulated the CRC Key words: glycolytic pathways, glycolysis related-genes, mem- cell lines by D-(+)-glucose and 2-deoxy-D-glucose (2-DG, a brane array, 2-deoxy-D-glucose, turmorigenesis, colorectal cancer non-metabolizable glucose analogue) and observed their effect on cell proliferation; in addition we inhibited the CRC cell line by 2-DG administration. Finally, we sought to clarify 81-91 11/12/07 12:26 Page 82 82 YEH et al: GLYCOLYTIC PATHWAYS AND GLYCOLYSIS-RELATED GENES IN CRC Table I. Clinicopathological characteristics of CRC patients. ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– Age Size No. Sex (years) (cm) Differentiationa Location UICC ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 3 F 54 4.2x3.0 MD Sigmoid colon II 9 F 48 8.8x5.6 PD Descending colon III 17 M 61 4.5x3.9 PD Descending colon III 20 M 70 2.0x1.5 WD Ascending colon I 25 F 58 6.7x2.9 MD Descending colon II 31 M 76 8.15x6.5 PD Rectum colon IV 45 M 27 5.0x3.8 MD Descending colon II 49 F 62 5.7x4.6 PD Descending colon III 64 F 55 3.0x4.5 WD Ascending colon I 75 M 71 10.5x5.7 MD Rectum II 78 M 70 5.85x4.1 PD Sigmoid colon IV 82 M 51 5.0x4.5 MD Descending colon II 85 F 59 7.2x6.2 PD Sigmoid colon IV 89 M 67 12.0x9.8 PD Rectum colon III 91 F 73 7.5x6.7 WD Rectum I 93 M 38 3.5x4.5 MD Rectum II 99 M 55 7.85x5.3 PD Sigmoid colon IV 102 F 93 4.0x3.5 MD Transverse colon II 116 F 85 8.2x3.7 PD Sigmoid colon IV 127 M 68 6.1x2.9 WD Ascending colon I 134 F 79 11.5x6.5 PD Sigmoid colon IV 143 M 71 10.5x7.8 PD Transverse colon III 157 M 66 5.8x4.0 PD Rectosigmoid colon III 179 F 53 3.8x7.2 WD Ascending colon I 207 F 66 3.2x2.9 MD Ascending colon II ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– aWD, well differentiated; MD, moderately differentiated; PD, poorly differentiated. ––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– the possible molecular mechanisms underlying the turmori- 2002). The results showed 5 patients with UICC stage I, 8 genesis of CRC and its association to the glycolytic pathway with UICC stage II, 6 with UICC stage III and 6 with UICC and glycolysis-related genes. stage IV CRC (Table I). The surgical tissue samples upon acquisition were frozen instantly in liquid nitrogen, and then Patients and methods stored at -80˚C until analysis. All sample acquisition and subsequent use was also approved by the Institutional Sample collection. Twenty-five patients, ranging in age from Review Board of the Kaohsiung Medical University Hospital. 27 to 93 years (mean, 63.04), who had undergone resection of CRC, were selected randomly from a patient group at the Total-RNA extraction and first strand cDNA synthesis. Total- Department of Surgery of Kaohsiung Medical University RNA was isolated from patient tissue and cell specimen Hospital between August 2004 and January 2006. None of samples with Isogen™ (Nippon Gene Co., Ltd., Toyama, these patients had received any preoperative radiotherapy or Japan) and QIAmp® RNA Blood Mini Kit (Qiagen Inc., chemotherapy. Soon after resection, the specimens were Valencia, CA) according to the manufacturer's instructions opened in the operating room and photographed for (17). The RNA concentration was determined spectrophoto- documentation. According to the prospective protocol, the metrically on the basis of absorbance at 260 nm (Beckman, tumors and all the lymph nodes were cut at different levels DU800, USA). First strand cDNA was synthesized from and embedded in paraffin, and sections were taken for total-RNA by using a RT-PCR kit (Promega Corp., Madison, routine H&E staining. Senior pathologists checked all the WI). The reverse transcription was carried out in a reaction slides and documented the pathological characteristics of the mixture consisting of 1X transcription optimized 5X buffer, tumor and lymph nodes. The tumor stage was defined 25 μg/ml oligo(dT)15mer primer, 100 mmol/l PCR nucleotide according to the criteria of the American Joint Commission mix, 200 μmol/l M-MLV reverse transcriptase, and 25 μl of on Cancer/International Union Against Cancer (AJCC/UICC, recombinant RNasin® ribonuclease inhibitor (Promega). The 81-91 11/12/07 12:26 Page 83 ONCOLOGY REPORTS 19: 81-91, 2008 83 reaction mixtures with RNA were incubated at 42˚C for (CCL-228 and CCL-227; ATCC, Rockville, MD). The cells longer than 2 h, heated to 95˚C for 5 min, and then stored at were maintained in Leibovitz's L-15 medium (Gibco Life -80˚C until analysis. Sciences, BRL, Grand Island, NY) supplemented with 10% (v/v) of fetal bovine serum (FBS) at 37˚C in humidified Oligo membrane array preparation. The procedure of the atmospheric air without CO2 addition. All media was supple- membrane-array method for the detection of CRC-related mented with 100 units/ml penicillin, 100 mg/ml streptomycin genes was performed in accordance with our previous work and 0.025 mg/ml fungizone. Cell density was maintained at (9-11). Visual OMP3 (oligonucleotide modeling platform, ~10,000 cells per milliliter of medium in T-25 flasks (Corning, DNA Software, Ann Arbor, MN) was applied to design oligo- NY). When grown to confluent monolayer, the cells were nucleotide probe sequences for target genes and ß-actin, and harvested by washing the dishes once with phosphate-buffered the latter served as an internal control (Table II).
Load more

Recommended publications
  • Phenotypic and Molecular Genetic Analysis of Pyruvate Kinase Deficiency in a Tunisian Family
    The Egyptian Journal of Medical Human Genetics (2016) 17, 265–270 HOSTED BY Ain Shams University The Egyptian Journal of Medical Human Genetics www.ejmhg.eg.net www.sciencedirect.com ORIGINAL ARTICLE Phenotypic and molecular genetic analysis of Pyruvate Kinase deficiency in a Tunisian family Jaouani Mouna a,1,*, Hamdi Nadia a,1, Chaouch Leila a, Kalai Miniar a, Mellouli Fethi b, Darragi Imen a, Boudriga Imen a, Chaouachi Dorra a, Bejaoui Mohamed b, Abbes Salem a a Laboratory of Molecular and Cellular Hematology, Pasteur Institute, Tunis, Tunisia b Service d’Immuno-He´matologie Pe´diatrique, Centre National de Greffe de Moelle Osseuse, Tunis, Tunisia Received 9 July 2015; accepted 6 September 2015 Available online 26 September 2015 KEYWORDS Abstract Pyruvate Kinase (PK) deficiency is the most frequent red cell enzymatic defect responsi- Pyruvate Kinase deficiency; ble for hereditary non-spherocytic hemolytic anemia. The disease has been studied in several ethnic Phenotypic and molecular groups. However, it is yet an unknown pathology in Tunisia. We report here, the phenotypic and investigation; molecular investigation of PK deficiency in a Tunisian family. Hemolytic anemia; This study was carried out on two Tunisian brothers and members of their family. Hematolog- Hydrops fetalis; ical, biochemical analysis and erythrocyte PK activity were performed. The molecular characteriza- PKLR mutation tion was carried out by gene sequencing technique. The first patient died few hours after birth by hydrops fetalis, the second one presented with neonatal jaundice and severe anemia necessitating urgent blood transfusion. This severe clinical pic- ture is the result of a homozygous mutation of PKLR gene at exon 8 (c.1079G>A; p.Cys360Tyr).
    [Show full text]
  • Eradication of ENO1-Deleted Glioblastoma Through Collateral Lethality
    bioRxiv preprint doi: https://doi.org/10.1101/331538; this version posted May 25, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Eradication of ENO1-deleted Glioblastoma through Collateral Lethality Yu-Hsi Lin1, Nikunj Satani1,2, Naima Hammoudi1, Jeffrey J. Ackroyd1, Sunada Khadka1, Victoria C. Yan1, Dimitra K. Georgiou1, Yuting Sun3, Rafal Zielinski4, Theresa Tran1, Susana Castro Pando1, Xiaobo Wang1, David Maxwell5, Zhenghong Peng6, Federica Pisaneschi1, Pijus Mandal7, Paul G. Leonard8, Quanyu Xu,9 Qi Wu9, Yongying Jiang9, Barbara Czako10, Zhijun Kang10, John M. Asara11, Waldemar Priebe4, William Bornmann12, Joseph R. Marszalek3, Ronald A. DePinho13 and Florian L. Muller#1 1) Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 2) Institute of Stroke and Cerebrovascular Disease, The University of Texas Health Science Center at Houston, TX 77030 3) Center for Co-Clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 4) Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 5) Institutional Analytics & Informatics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 6) Cardtronics, Inc., Houston, TX 77042 7) Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054 bioRxiv preprint doi: https://doi.org/10.1101/331538; this version posted May 25, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
    [Show full text]
  • The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines Received: 07 August 2015 1 1 2 3,4 Accepted: 27 October 2015 Maurice A
    www.nature.com/scientificreports OPEN The Molecular Karyotype of 25 Clinical-Grade Human Embryonic Stem Cell Lines Received: 07 August 2015 1 1 2 3,4 Accepted: 27 October 2015 Maurice A. Canham , Amy Van Deusen , Daniel R. Brison , Paul A. De Sousa , 3 5 6 5 7 Published: 26 November 2015 Janet Downie , Liani Devito , Zoe A. Hewitt , Dusko Ilic , Susan J. Kimber , Harry D. Moore6, Helen Murray3 & Tilo Kunath1 The application of human embryonic stem cell (hESC) derivatives to regenerative medicine is now becoming a reality. Although the vast majority of hESC lines have been derived for research purposes only, about 50 lines have been established under Good Manufacturing Practice (GMP) conditions. Cell types differentiated from these designated lines may be used as a cell therapy to treat macular degeneration, Parkinson’s, Huntington’s, diabetes, osteoarthritis and other degenerative conditions. It is essential to know the genetic stability of the hESC lines before progressing to clinical trials. We evaluated the molecular karyotype of 25 clinical-grade hESC lines by whole-genome single nucleotide polymorphism (SNP) array analysis. A total of 15 unique copy number variations (CNVs) greater than 100 kb were detected, most of which were found to be naturally occurring in the human population and none were associated with culture adaptation. In addition, three copy-neutral loss of heterozygosity (CN-LOH) regions greater than 1 Mb were observed and all were relatively small and interstitial suggesting they did not arise in culture. The large number of available clinical-grade hESC lines with defined molecular karyotypes provides a substantial starting platform from which the development of pre-clinical and clinical trials in regenerative medicine can be realised.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • 1 Metabolic Dysfunction Is Restricted to the Sciatic Nerve in Experimental
    Page 1 of 255 Diabetes Metabolic dysfunction is restricted to the sciatic nerve in experimental diabetic neuropathy Oliver J. Freeman1,2, Richard D. Unwin2,3, Andrew W. Dowsey2,3, Paul Begley2,3, Sumia Ali1, Katherine A. Hollywood2,3, Nitin Rustogi2,3, Rasmus S. Petersen1, Warwick B. Dunn2,3†, Garth J.S. Cooper2,3,4,5* & Natalie J. Gardiner1* 1 Faculty of Life Sciences, University of Manchester, UK 2 Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, Manchester, UK 3 Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, UK 4 School of Biological Sciences, University of Auckland, New Zealand 5 Department of Pharmacology, Medical Sciences Division, University of Oxford, UK † Present address: School of Biosciences, University of Birmingham, UK *Joint corresponding authors: Natalie J. Gardiner and Garth J.S. Cooper Email: [email protected]; [email protected] Address: University of Manchester, AV Hill Building, Oxford Road, Manchester, M13 9PT, United Kingdom Telephone: +44 161 275 5768; +44 161 701 0240 Word count: 4,490 Number of tables: 1, Number of figures: 6 Running title: Metabolic dysfunction in diabetic neuropathy 1 Diabetes Publish Ahead of Print, published online October 15, 2015 Diabetes Page 2 of 255 Abstract High glucose levels in the peripheral nervous system (PNS) have been implicated in the pathogenesis of diabetic neuropathy (DN). However our understanding of the molecular mechanisms which cause the marked distal pathology is incomplete. Here we performed a comprehensive, system-wide analysis of the PNS of a rodent model of DN.
    [Show full text]
  • Reduced Expression of Pyruvate Kinase in Kidney Proximal Tubule
    www.nature.com/scientificreports OPEN Reduced expression of pyruvate kinase in kidney proximal tubule cells is a potential mechanism Received: 29 March 2018 Accepted: 22 January 2019 of pravastatin altered glucose Published: xx xx xxxx metabolism Yong Pyo Lee1, Yuri Cho2, Eun Jee Kim2,3, Hyojung Lee2, Hoon Young Choi4, Hye Jin Wang5, Eun Seok Kang 5, Yu Seun Kim2,6, Myoung Soo Kim1,2,6 & Beom Seok Kim2,3,7 Recent studies have reported that statins are associated with increased incidence of diabetes. Although several mechanisms have been proposed, the role of the kidney’s glucose metabolism upon statin treatment is still unclear. Thus, we investigated the role of pravastatin in gluconeogenesis and glycolysis. HK-2 and HepG2 cells were treated with pravastatin and cultured under either high- or normal-cholesterol conditions. In HK-2 cells treated with pravastatin under both high- and normal- cholesterol conditions, the protein expression of only pyruvate kinase isozymes L/R (PKLR) decreased in a dose-dependent manner, while the protein expression of other glucose metabolism related enzymes remained unchanged. Within the in vivo experiment, male C57BL/6 mice were fed either pravastatin-treated normal-fat diets for 2 or 4 weeks or pravastatin-treated high-fat diets for 16 weeks. Protein expression of PKLR in the kidneys from mice that consumed pravastatin-treated high-fat diets decreased signifcantly compared to the controls. Upon the treatments of pravastatin, only the PKLR expression decreased in lean mice. Furthermore, PKLR activity decreased signifcantly in the kidney after pravastatin treatments. However, there was no change in enzyme activity in the liver, suggesting that pravastatin decreased PKLR activity only in the kidney.
    [Show full text]
  • Liver Glucose Metabolism in Humans
    Biosci. Rep. (2016) / 36 / art:e00416 / doi 10.1042/BSR20160385 Liver glucose metabolism in humans Mar´ıa M. Adeva-Andany*1, Noemi Perez-Felpete*,´ Carlos Fernandez-Fern´ andez*,´ Cristobal´ Donapetry-Garc´ıa* and Cristina Pazos-Garc´ıa* *Nephrology Division, Hospital General Juan Cardona, c/ Pardo Bazan´ s/n, 15406 Ferrol, Spain Synopsis Information about normal hepatic glucose metabolism may help to understand pathogenic mechanisms underlying obesity and diabetes mellitus. In addition, liver glucose metabolism is involved in glycosylation reactions and con- nected with fatty acid metabolism. The liver receives dietary carbohydrates directly from the intestine via the portal vein. Glucokinase phosphorylates glucose to glucose 6-phosphate inside the hepatocyte, ensuring that an adequate flow of glucose enters the cell to be metabolized. Glucose 6-phosphate may proceed to several metabolic path- ways. During the post-prandial period, most glucose 6-phosphate is used to synthesize glycogen via the formation of glucose 1-phosphate and UDP–glucose. Minor amounts of UDP–glucose are used to form UDP–glucuronate and UDP– galactose, which are donors of monosaccharide units used in glycosylation. A second pathway of glucose 6-phosphate metabolism is the formation of fructose 6-phosphate, which may either start the hexosamine pathway to produce UDP-N-acetylglucosamine or follow the glycolytic pathway to generate pyruvate and then acetyl-CoA. Acetyl-CoA may enter the tricarboxylic acid (TCA) cycle to be oxidized or may be exported to the cytosol to synthesize fatty acids, when excess glucose is present within the hepatocyte. Finally, glucose 6-phosphate may produce NADPH and ribose 5-phosphate through the pentose phosphate pathway.
    [Show full text]
  • Supporting Information
    Supporting Information Wakabayashi et al. 10.1073/pnas.1521754113 SI Materials and Methods DNA Transfection and Puromycin Selection. K562 cells were cotrans- Plasmid Preparation. Short guide RNA (sgRNA) sequences (Table fected with 1 μg total of Cas9 nuclease and sgRNA plasmids using S1) were cloned into the pSg1 vector (Addgene) and the XPR5 Lipofectamine LTX Plus Reagent (Thermo Fisher Scientific) at a lentiviral vector (Broad Institute), respectively. [The XPR5 1:2 ratio of Cas9 to sgRNA. For a control, K562 cells were co- vector contains the Cas9 nuclease and a red fluorescent protein transfectedwith1μg total of Cas9 nuclease and pLKO.1-GFP (RFP) cassette.] The Cas9 nuclease expression vector used was plasmid at a 1:2 ratio of Cas9 to pLKO.1-GFP. At 24 h after co- μ pxPR_BRD001, which contains a puromycin resistance cassette transfection, puromycin was added at a concentration of 2 g/mL, μ as a selection marker. Off-target scores for each guide were followed 24 h later by a reduction to 1 g/mL for an additional 24 h. calculated using the CRISPR design tool (CRISPR Design; Selection efficiency was assessed by flow cytometry with propidium crispr.mit.edu); only guides with a score >50 (except for a score iodide staining (to assess viability) on a FACSCanto II flow cy- of 49 in one case) were used. tometer (BD Biosciences). Limiting dilutions were performed to obtain single cell-derived clonal populations for both cells targeted Cell Culture and Lentivirus Production. The K562 cells (American with sgRNAs as well as for GFP controls. Unless specified other- Type Culture Collection) were maintained in RPMI medium 1640 wise, three matching clonal GFP controls were analyzed for each plus L-glutamine (Life Technologies) supplemented with 10% experiment.
    [Show full text]
  • Peripheral Glycolysis in Neurodegenerative Diseases
    International Journal of Molecular Sciences Review Peripheral Glycolysis in Neurodegenerative Diseases Simon M. Bell * , Toby Burgess, James Lee, Daniel J. Blackburn, Scott P. Allen and Heather Mortiboys Sheffield Institute for Translational Neurosciences, University of Sheffield, Sheffield S10 2HQ, UK; t.burgess@sheffield.ac.uk (T.B.); james.lee@sheffield.ac.uk (J.L.); d.blackburn@sheffield.ac.uk (D.J.B.); s.p.allen@sheffield.ac.uk (S.P.A.); [email protected] (H.M.) * Correspondence: s.m.bell@sheffield.ac.uk; Tel.: +44-(0)-114-2222273 Received: 31 October 2020; Accepted: 21 November 2020; Published: 24 November 2020 Abstract: Neurodegenerative diseases are a group of nervous system conditions characterised pathologically by the abnormal deposition of protein throughout the brain and spinal cord. One common pathophysiological change seen in all neurodegenerative disease is a change to the metabolic function of nervous system and peripheral cells. Glycolysis is the conversion of glucose to pyruvate or lactate which results in the generation of ATP and has been shown to be abnormal in peripheral cells in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis. Changes to the glycolytic pathway are seen early in neurodegenerative disease and highlight how in multiple neurodegenerative conditions pathology is not always confined to the nervous system. In this paper, we review the abnormalities described in glycolysis in the three most common neurodegenerative diseases. We show that in all three diseases glycolytic changes are seen in fibroblasts, and red blood cells, and that liver, kidney, muscle and white blood cells have abnormal glycolysis in certain diseases.
    [Show full text]
  • Hematology Test Requisition
    GENETICS AND GENOMICS DIAGNOSTIC LABORATORY Mailing Address: For local courier service and/or inquiries, please contact 513-636-4474 • Fax: 513-636-4373 3333 Burnet Avenue, Room R1042 www.cincinnatichildrens.org/moleculargenetics • Email: [email protected] Cincinnati, OH 45229 HEMATOLOGY TEST REQUISITION All Information Must Be Completed Before Sample Can Be Processed PATIENT INFORMATION ETHNIC/RACIAL BACKGROUND (Choose All) Patient Name: _____________________, ___________________, ________ European American (White) African-American (Black) Last First MI Native American or Alaskan Asian-American Address: _____________________________________________________ Pacific Islander Ashkenazi Jewish ancestry _____________________________________________________ Latino-Hispanic _____________________________________________ Home Phone: _________________________________________________ (specify country/region of origin) MR# __________________ Date of Birth ________ /________ / ________ Other ____________________________________________________ (specify country/region of origin) Sex: Male Female BILLING INFORMATION REFERRING PHYSICIAN o REFERRING INSTITUTION Physician Name (print): _________________________________________ Institution: ____________________________________________________ Address: ____________________________________________________ Address: _____________________________________________________ Phone: ( _______ ) _______________ Fax: ( _______ ) _______________ City/State/Zip: _________________________________________________
    [Show full text]
  • PIM2-Mediated Phosphorylation of Hexokinase 2 Is Critical for Tumor Growth and Paclitaxel Resistance in Breast Cancer
    Oncogene (2018) 37:5997–6009 https://doi.org/10.1038/s41388-018-0386-x ARTICLE PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer 1 1 1 1 1 2 2 3 Tingting Yang ● Chune Ren ● Pengyun Qiao ● Xue Han ● Li Wang ● Shijun Lv ● Yonghong Sun ● Zhijun Liu ● 3 1 Yu Du ● Zhenhai Yu Received: 3 December 2017 / Revised: 30 May 2018 / Accepted: 31 May 2018 / Published online: 9 July 2018 © The Author(s) 2018. This article is published with open access Abstract Hexokinase-II (HK2) is a key enzyme involved in glycolysis, which is required for breast cancer progression. However, the underlying post-translational mechanisms of HK2 activity are poorly understood. Here, we showed that Proviral Insertion in Murine Lymphomas 2 (PIM2) directly bound to HK2 and phosphorylated HK2 on Thr473. Biochemical analyses demonstrated that phosphorylated HK2 Thr473 promoted its protein stability through the chaperone-mediated autophagy (CMA) pathway, and the levels of PIM2 and pThr473-HK2 proteins were positively correlated with each other in human breast cancer. Furthermore, phosphorylation of HK2 on Thr473 increased HK2 enzyme activity and glycolysis, and 1234567890();,: 1234567890();,: enhanced glucose starvation-induced autophagy. As a result, phosphorylated HK2 Thr473 promoted breast cancer cell growth in vitro and in vivo. Interestingly, PIM2 kinase inhibitor SMI-4a could abrogate the effects of phosphorylated HK2 Thr473 on paclitaxel resistance in vitro and in vivo. Taken together, our findings indicated that PIM2 was a novel regulator of HK2, and suggested a new strategy to treat breast cancer. Introduction ATP molecules.
    [Show full text]
  • Association of Polymorphisms in the Telomere-Related Gene ACYP2 with Lung Cancer Risk in the Chinese Han Population
    www.impactjournals.com/oncotarget/ Oncotarget, 2016, Vol. 7, (No. 52), pp: 87473-87478 Research Paper Association of polymorphisms in the telomere-related gene ACYP2 with lung cancer risk in the Chinese Han population Nanzheng Chen1,*, Xiaomei Yang2,*, Wen Guo3, Jiangtao You1, Qifei Wu1, Guangjian Zhang1, Haijun Li1, Donghong Geng4, Tianbo Jin5, Junke Fu1, Yong Zhang1 1Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China 2Hospital 521 of China’s Ordnance Industry Group, Xi’an 710065, Shaanxi, China 3Inner Mongolia Medical University, Hohhot 010050, Inner Mongolia, China 4School of Continuing Education of Xi’an Jiaotong University, Xi’an 710061, Shaanxi, China 5School of Life Sciences, Northwest University, Xi’an 710069, Shaanxi, China *These authors have contributed equally to this work Correspondence to: Junke Fu, email: [email protected] Yong Zhang, email: [email protected] Keywords: association study, lung cancer, telomere-related gene, single nucleotide polymorphisms (SNPs) Received: August 26, 2016 Accepted: October 14, 2016 Published: December 10, 2016 ABSTRACT Single nucleotide polymorphisms (SNPs) in the telomere-associated gene ACYP2 are associated with increased lung cancer risk. We explored the correlation between ACYP2 SNPs and lung cancer susceptibility in the Chinese Han population. A total of 554 lung cancer patients and 603 healthy controls were included in this study. Thirteen SNPs in ACYP2 were selected. Odds ratios (ORs) and 95% confidence intervals
    [Show full text]